- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05213234
Chronotherapy of 5-Aminosalicylic Acid in Ulcerative Colitis
Chronotherapy of 5-Aminosalicylic Acid in Ulcerative Colitis: A Randomized Crossover Trial
The hypothesis of this study is that appropriate time of day of administration of oral, once daily 5-ASA therapy in alignment with the host circadian rhythms will improve subclinical inflammation and microbial structure/function and increase mucosal 5-ASA levels.
All subjects will be randomized to once daily 5-ASA medications at two different times of the day: between 06:00 - 10:00 h or 18:00 - 22:00 h. Three disease assessments will performed at: 1) enrollment just before randomization; 2) month 3, at the completion of first arm (Condition 1), and 3) month 6, after completion of the second arm (Condition 2). During these study time points, participants will be asked to complete questionnaires, track their 5-ASA medication usage, provide a stool sample, blood draw, urine test, wear a watch to measure sleep patterns, and complete a flexible sigmoidoscopy.
Study Overview
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Daynia Sanchez-Bass
- Phone Number: (312) 563-4981
- Email: Daynia_Sanchez-Bass@rush.edu
Study Contact Backup
- Name: Ali Keshavarzian, M.D.
- Phone Number: 312-563-4175
- Email: ali_keshavarzian@rush.edu
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60068
- Recruiting
- Rush University Medical Center
-
Contact:
- Michelle Villanueva
- Phone Number: 312-942-8927
- Email: Michelle_Villanueva@rush.edu
-
Contact:
- Daynia Sanchez-Bass
- Phone Number: 312-563-4981
- Email: Daynia_Sanchez-Bass@rush.edu
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Not yet recruiting
- The Medical University of South Carolina
-
Contact:
- Garth R Swanson, M.D.
- Phone Number: 843-876-2152
- Email: swansong@musc.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- M/F, 18-65 years of age
- Ulcerative Colitis with Inactive Disease (Mayo Score ≤ 2; partial Mayo Score ≤ 1 with endoscopic score 0-1)
- Subclinical inflammation (stool calprotectin >50 or CRP > 8 mg/L)
- Stable medications with no disease flares for the > 3 months
- Normal psychological evaluation and negative drug screen (See Below)
Exclusion Criteria:
- Active UC at enrollment (Mayo > 2 and/or sigmoidoscopy score of 2 or 3)
- Prior ostomy or subtotal colectomy
- Recent prednisone or antibiotic use in last 12 weeks
- Use of biologic or immunomodulatory medications (i.e. Infliximab, Adalimumab, azathioprine, Vedolizumab, methotrexate, etc.)
- Major Depression identified as Beck Depression Inventory (score ≥14)
- Restless leg syndrome (score ≥ 15 on the IRLS Study Group Rating Scale)
- Sleep apnea (score high risk ≥ 2 or more categories on the Berlin Questionnaire)
- Clinically significant diabetes (Hgb-A1c>7)
- Regular use of medications that affect intestinal permeability, intestinal motility and/or NSAIDs, products during 4 weeks prior to the study
- Atypical American diet (FFQ 5-15 g fiber per day)
- Clinically significant cardiac, renal (creatinine > twice normal) or liver disease
- Alcohol use disorder (AUDIT>8)
- Chronic use of illicit drugs
- Shift Work
- Children under 6 months
- Inability to sign an informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Morning Medication Administration
Subjects are directed to take their medication between 06:00 and 10:00.
|
Chronotherapy is a behavioral intervention that has the intended effect of maximizing therapeutic benefit of a drug by coordinating intake times and biological rhythms.
|
Other: Night Medication Administration
Subjects are directed to take their medication between 18:00 and 22:00.
|
Chronotherapy is a behavioral intervention that has the intended effect of maximizing therapeutic benefit of a drug by coordinating intake times and biological rhythms.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Stool Calprotectin from Baseline to Morning Medication Administration to Night Medication Administration
Time Frame: 10 minute stool collection at Baseline, 10 minute stool collection at Morning Medication Administration, and 10 minute stool collection at Night Medication Administration
|
ELISA
|
10 minute stool collection at Baseline, 10 minute stool collection at Morning Medication Administration, and 10 minute stool collection at Night Medication Administration
|
Change in Mucosal 5-ASA Concentration from Baseline to Morning Medication Administration to Night Medication Administration
Time Frame: 30 minute flexible sigmoidoscopy at Baseline, 30 minute flexible sigmoidoscopy at Morning Medication Administration, and 30 minute flexible sigmoidoscopy at Night Medication Administration
|
HPLC of tissue samples taken during flexible sigmoidoscopy at Baseline, Morning Medication Administration and Night Medication Administration
|
30 minute flexible sigmoidoscopy at Baseline, 30 minute flexible sigmoidoscopy at Morning Medication Administration, and 30 minute flexible sigmoidoscopy at Night Medication Administration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Intestinal Permeability from Baseline to Morning Medication Administration to Night Medication Administration
Time Frame: 24 hour urine collection at baseline, 24 hour urine collection at Morning Medication Administration, and 24 hour urine collection at Night Medication Administration
|
Intestinal permeability is assessed through spectrophotometric measurements of sucralose, sucrose, maltose and lactulose concentrations in urine following ingestion of a sugar cocktail.
|
24 hour urine collection at baseline, 24 hour urine collection at Morning Medication Administration, and 24 hour urine collection at Night Medication Administration
|
Change in Serum Cytokines from Baseline to Morning Medication Administration to Night Medication Administration
Time Frame: Single blood draw at baseline, single blood draw at Morning Medication Administration, and single blood draw at Night Medication Administration
|
LBP, LPS, zonulin, and sCD14
|
Single blood draw at baseline, single blood draw at Morning Medication Administration, and single blood draw at Night Medication Administration
|
Change in Mayo Score from Baseline to Morning Medication Administration to Night Medication Administration
Time Frame: 5 minute questionnaire at Baseline, 5 minute questionnaire at Morning Medication Administration, 5 minute questionnaire at Night Medication Administration
|
Mayo Score
|
5 minute questionnaire at Baseline, 5 minute questionnaire at Morning Medication Administration, 5 minute questionnaire at Night Medication Administration
|
Change in Circadian Rhythms from Baseline to Morning Medication Administration to Night Medication Administration
Time Frame: Wrist Actigraphy Watch worn for two weeks at Baseline, two weeks at Morning Medication Administration, and two weeks at night medication administration
|
Wrist Actigraphy
|
Wrist Actigraphy Watch worn for two weeks at Baseline, two weeks at Morning Medication Administration, and two weeks at night medication administration
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 20052807
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ulcerative Colitis
-
Ferring PharmaceuticalsCompletedActive Ulcerative Colitis | Remission of Ulcerative ColitisCanada
-
Palatin Technologies, IncRecruitingUlcerative Colitis | Ulcerative Colitis Flare | Ulcerative Colitis Acute | UlcerativeUnited States
-
Theravance BiopharmaCompletedUlcerative Colitis, Active Severe | Ulcerative Colitis, Active ModerateUnited States, Georgia, Moldova, Republic of, Romania
-
Rise Therapeutics LLCUniversity of Colorado, Denver; Mayo ClinicRecruitingUlcerative Colitis | Ulcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic | Ulcerative Colitis Chronic MildUnited States
-
Assistance Publique - Hôpitaux de ParisMRSU 938 - Research Center of Saint AntoineNot yet recruitingPediatric Ulcerative Colitis in RemissionFrance
-
Protagonist Therapeutics, Inc.CompletedUlcerative Colitis Chronic Moderate | Ulcerative Colitis Chronic SevereUnited States, Austria, Bulgaria, Canada, Georgia, Germany, Hungary, Italy, Korea, Republic of, Poland, Russian Federation, Serbia, Ukraine
-
Theravance BiopharmaCompletedActive Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy SubjectsUnited States
-
Altheus Therapeutics, Inc.UnknownUlcerative Colitis | Left-sided Ulcerative Colitis | Distal Ulcerative ColitisUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...University Medical Center Groningen; UMC UtrechtRecruitingUlcerative Colitis | Ulcerative Colitis Flare | Ulcerative Colitis AcuteNetherlands
-
Immune PharmaceuticalsUnknownUlcerative Colitis, Active Severe | Ulcerative Colitis, Active ModerateIsrael
Clinical Trials on Chronotherapy
-
Rhode Island HospitalNorthwell Health; University of North Carolina, Chapel HillRecruitingDepression | Postpartum Depression | Sleep Disturbance | Pregnancy Related | Circadian Dysregulation | Prenatal DisorderUnited States
-
Rhode Island HospitalNational Institute of Mental Health (NIMH); The Depressive and Bipolar Disorder...CompletedDepression | Postpartum Depression | Major Depressive DisorderUnited States
-
Billings ClinicCompletedSuicidal Ideation | Depressive Disorder, Major | Bipolar DepressionUnited States
-
Medical University of South CarolinaCompletedBipolar Depression | Non-Psychotic Unipolar DepressionUnited States
-
University of California, BerkeleyCompletedEveningness/SleepUnited States
-
Northwell HealthWithdrawnHypertensionUnited States
-
University of FloridaTerminated
-
University of PittsburghNational Institute on Aging (NIA)CompletedHypertension | Sleep Disturbance | NocturiaUnited States
-
University of California, BerkeleyCompleted